Cancer name Bladder Cancer
Cancer Type BLCA
Immunotherapy type Immune Checkpoint Therapy;Immunostimulant OR Targeting Therapy
Treatment anti-PD1 Ab
Drugstatus NA
Drugbank ID NA
Checkpoints PD-1
Signature Type Cell
Signature CD8+ T cells
Official Symbol Naive CD8+ T cell
Mode of action CE_D_UP
Description for ‘mode of action’：the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation)，Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental Mouse model
Description To determine whether dinaci-clib boosts or inhibits anti-PD1–mediated enhancement of T cell responses, we examined T cell infiltration and activation in the tumor. We treated BALB/c mice with established CT26 tumors with dinaciclib and anti-PD1 as before. On day 14 after treatment initiation (i.e., 2 days after the fourth dose), tumors were harvest-ed and analyzed by flow cytometry. Compared with dinaciclib and anti-PD1 monotherapies, we found that combination treatment increased the number of tumor-infiltrating CD8+ and CD4+ T cells, and we observed a similar increase in the number of CD8+ T cells in the MC38 and MB49 tumor models.
PMID 29337311
Title Dinaciclib induces immunogenic cell death and enhances anti-PD1–mediated tumor suppression